CN1997749A - 生物分子分隔基序及其用途 - Google Patents

生物分子分隔基序及其用途 Download PDF

Info

Publication number
CN1997749A
CN1997749A CNA200480040802XA CN200480040802A CN1997749A CN 1997749 A CN1997749 A CN 1997749A CN A200480040802X A CNA200480040802X A CN A200480040802XA CN 200480040802 A CN200480040802 A CN 200480040802A CN 1997749 A CN1997749 A CN 1997749A
Authority
CN
China
Prior art keywords
polypeptide
seq
cell
described method
biomolecule partition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200480040802XA
Other languages
English (en)
Chinese (zh)
Inventor
M·李
S·鹿野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CN1997749A publication Critical patent/CN1997749A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
CNA200480040802XA 2003-11-21 2004-11-22 生物分子分隔基序及其用途 Pending CN1997749A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52438003P 2003-11-21 2003-11-21
US60/524,380 2003-11-21

Publications (1)

Publication Number Publication Date
CN1997749A true CN1997749A (zh) 2007-07-11

Family

ID=34652267

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200480040802XA Pending CN1997749A (zh) 2003-11-21 2004-11-22 生物分子分隔基序及其用途

Country Status (6)

Country Link
US (1) US7732165B2 (enExample)
EP (1) EP1701772A4 (enExample)
JP (1) JP4790624B2 (enExample)
CN (1) CN1997749A (enExample)
AU (1) AU2004294933B2 (enExample)
WO (1) WO2005053811A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111870700A (zh) * 2020-08-12 2020-11-03 中国科学院昆明动物研究所 十八烷基化修饰的r18-7aa多肽及其衍生多肽的应用

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE482214T1 (de) * 2005-06-14 2010-10-15 Schering Corp Aspartylproteasehemmer
US9238150B2 (en) 2005-07-22 2016-01-19 The Board Of Trustees Of The Leland Stanford Junior University Optical tissue interface method and apparatus for stimulating cells
EP2465925A1 (en) * 2005-07-22 2012-06-20 The Board Of Trustees Of The Leland Light-activated cation channel and uses thereof
US8926959B2 (en) * 2005-07-22 2015-01-06 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
US10052497B2 (en) 2005-07-22 2018-08-21 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US7763606B2 (en) * 2005-10-27 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2008086470A1 (en) 2007-01-10 2008-07-17 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US8401609B2 (en) 2007-02-14 2013-03-19 The Board Of Trustees Of The Leland Stanford Junior University System, method and applications involving identification of biological circuits such as neurological characteristics
WO2008106694A2 (en) 2007-03-01 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
US10434327B2 (en) 2007-10-31 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Implantable optical stimulators
US10035027B2 (en) 2007-10-31 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Device and method for ultrasonic neuromodulation via stereotactic frame based technique
BRPI0819063A2 (pt) * 2007-11-27 2020-08-18 The University Of British Columbia método para tratamento de artrite, anticorpo, hibridoma, antagonista de 14-3-3, usos de um antagonista de 14-3-3, composições farmacêuticas, método para redução da expressão de mmp no sinóvio de um paciente e usos de uma composição farmacêutica
US8603790B2 (en) 2008-04-23 2013-12-10 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
ES2426095T3 (es) 2008-05-29 2013-10-21 The Board Of Trustees Of The Leland Stanford Junior University Línea celular, sistema y procedimiento para el control óptico de mensajeros secundarios
WO2009155369A1 (en) 2008-06-17 2009-12-23 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for controlling cellular development
SG191593A1 (en) 2008-06-17 2013-07-31 Univ Leland Stanford Junior Methods, systems and devices for optical stimulation of target cells using an optical transmission element
WO2010006049A1 (en) 2008-07-08 2010-01-14 The Board Of Trustees Of The Leland Stanford Junior University Materials and approaches for optical stimulation of the peripheral nervous system
NZ602416A (en) 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto
DK2406633T3 (en) 2009-03-11 2019-04-01 Augurex Life Sciences Corp COMPOSITIONS AND PROCEDURES FOR CHARACTERIZING ARTHRITIC CONDITIONS
US9134323B2 (en) 2009-12-01 2015-09-15 The Rockefeller University Antibody that specifically binds to an epitope in the tureet region of a human Kir channel
CA2791094A1 (en) 2010-03-17 2011-09-22 The Board Of Trustees Of The Leland Stanford Junior University Light-sensitive ion-passing molecules
CN103491770B (zh) 2010-11-05 2016-06-08 斯坦福大学托管董事会 稳定阶跃函数视蛋白及其使用方法
CA2816972C (en) 2010-11-05 2019-12-03 The Board Of Trustees Of The Leland Stanford Junior University Control and characterization of memory function
EP3225108A1 (en) 2010-11-05 2017-10-04 The Board of Trustees of The Leland Stanford Junior University Optogenetic control of reward-related behaviors
WO2012061676A1 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University Light-activated chimeric opsins and methods of using the same
CA3056186A1 (en) 2010-11-05 2012-05-10 Board Of Trustees Of The Leland Stanford Junior University Optically-controlled cns dysfunction
CN103313752B (zh) 2010-11-05 2016-10-19 斯坦福大学托管董事会 用于光遗传学方法的光的上转换
US8696722B2 (en) 2010-11-22 2014-04-15 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic magnetic resonance imaging
WO2013056377A1 (en) 2011-10-21 2013-04-25 Augurex Life Sciences Corporation Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
US9365628B2 (en) * 2011-12-16 2016-06-14 The Board Of Trustees Of The Leland Stanford Junior University Opsin polypeptides and methods of use thereof
CA2865296A1 (en) 2012-02-21 2013-08-29 Karl A. DEISSEROTH Compositions and methods for treating neurogenic disorders of the pelvic floor
US9636380B2 (en) 2013-03-15 2017-05-02 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of inputs to the ventral tegmental area
EP2968997B1 (en) 2013-03-15 2019-06-26 The Board of Trustees of the Leland Stanford Junior University Optogenetic control of behavioral state
CA2908864A1 (en) 2013-04-29 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Devices, systems and methods for optogenetic modulation of action potentials in target cells
WO2015023782A1 (en) 2013-08-14 2015-02-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for controlling pain
WO2016209654A1 (en) 2015-06-22 2016-12-29 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
US11294165B2 (en) 2017-03-30 2022-04-05 The Board Of Trustees Of The Leland Stanford Junior University Modular, electro-optical device for increasing the imaging field of view using time-sequential capture

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856155A (en) 1996-02-23 1999-01-05 The Johns Hopkins University School Of Medicine Compounds and related methods for modulating potassium ion channels and assays for such compounds
WO1997044491A1 (en) 1996-05-22 1997-11-27 The Johns Hopkins University Methods of detection utilizing modified bacteriophage
AU7410998A (en) 1996-11-26 1998-06-22 Johns Hopkins University, The Ligand detection system and methods of use thereof
WO2001014539A2 (en) 1999-08-20 2001-03-01 Johns Hopkins University School Of Medicine Methods and compositions for the construction and use of fusion libraries
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111870700A (zh) * 2020-08-12 2020-11-03 中国科学院昆明动物研究所 十八烷基化修饰的r18-7aa多肽及其衍生多肽的应用

Also Published As

Publication number Publication date
JP2007525207A (ja) 2007-09-06
AU2004294933A1 (en) 2005-06-16
JP4790624B2 (ja) 2011-10-12
US20070031924A1 (en) 2007-02-08
US7732165B2 (en) 2010-06-08
WO2005053811A2 (en) 2005-06-16
EP1701772A2 (en) 2006-09-20
AU2004294933B2 (en) 2011-11-17
WO2005053811A3 (en) 2007-03-29
EP1701772A4 (en) 2012-03-28

Similar Documents

Publication Publication Date Title
CN1997749A (zh) 生物分子分隔基序及其用途
CN103990122B (zh) osteoprotegerin 结合蛋白和受体
Sadée et al. Biology of membrane transport proteins
CN109562146A (zh) 血清白蛋白结合纤连蛋白iii型结构域
CA2142819C (en) Glucagon receptors
WO2018050039A1 (zh) 新的抗pd-1纳米抗体及其应用
JPS61501627A (ja) ヒトエリスロポエチンをコードするｄｎａ
CA2385444C (en) Humanin, a polypeptide suppressing neuronal death
CN111499725A (zh) 结合IL-4受体α的泪脂质运载蛋白突变蛋白
DE69634421T2 (de) Gene und genprodukte bezogen auf das werner-syndrom
US6723841B2 (en) Corticotropin-releasing factor2 receptors
US11319348B2 (en) Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
US5776725A (en) Recombinant production of glucagon receptors
CN109111517A (zh) 一种经修饰的生长分化因子及其制备方法和应用
JP2008500015A (ja) 血管形成ペプチドおよびその使用
CN101627053A (zh) 泛细胞表面受体特异的治疗剂
CN110172103A (zh) GLP-1类似物-Fc融合蛋白及其制备方法和用途
JP2001527402A (ja) Ｎｇｆ変異体
CN106008717A (zh) 一种长效重组glp-1融合蛋白及其制备方法和用途
WO2005035580A9 (de) Single-chain-antikörper gegen den 37 kda/67 kda lamininrezeptor als werkzeuge zur diagnose und therapie von prionerkrankungen und krebs, deren herstellung und verwendung
CN114767832A (zh) 多肽及其用途
CA2531228A1 (en) Novel therapeutic fusion proteins
EP0860501A2 (en) Corticotropin-releasing factor2 receptors
TWI278319B (en) VGF selective binding agents and methods of treating VGF-related disorders
CN119431515A (zh) 一种穿膜蛋白及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20070711